Last edition
News about "Tempus AI"
Tempus Launches Next-Generation Lens AI Platform for Oncology Drug Development
Tempus has unveiled the next-generation Lens platform, expanding its agentic AI capabilities for oncology drug development by leveraging over a decade of longitudinal real-world data and advanced analytics to generate actionable insights for biopharma research, clinical development, and precision medicine.
Tempus AI | 01/06/2026 | By News Bureau | 163
Tempus Wins FDA Approval for xT CDx, Expanding Solid Tumor Testing Portfolio
Tempus has received US FDA approval for its tumor-only xT CDx, becoming the first laboratory with companion diagnostic approval for both tumor-only and tumor-normal genomic profiling.
Tempus AI | 30/05/2026 | By News Bureau | 104
Tempus AI Expands Strategic Partnership with Bristol Myers Squibb
Tempus AI expands its collaboration with Bristol Myers Squibb to use Artificial Intelligence (AI) and real-world data for optimising oncology and neuroscience clinical trials and improving regulatory success rates.
Tempus AI | 15/05/2026 | By News Bureau | 246
Median Technologies, a France-based developer of artificial intelligence-powered software as a medical device, has entered a non-exclusive distribution agreement with Tempus AI, Inc. to commercialise its Eyonis LCS lung screening platform in the United States.
Tempus AI | 15/02/2026 | By Darshana | 290
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy